Pyxis Oncology Inc.
PYXS | NASDAQ
$3.33
+$0.14 (+4.39%)
Sep 22, 2026, 12:01 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 13.86M | 16.15M | n/a | n/a | n/a | n/a |
Cost of Revenue | 2.39M | 475K | n/a | n/a | n/a | 444K |
Gross Profit | 11.47M | 15.67M | n/a | n/a | n/a | -444K |
Operating Income | -84.42M | -89.46M | -82.2M | -123.48M | -69.72M | -12.89M |
Interest Income | 3.61M | 7.04M | 6.63M | 2.76M | 23K | 66K |
Pretax Income | -78.24M | -79.5M | -73.79M | -120.72M | -75.98M | -12.83M |
Net Income | -79.62M | -77.33M | -73.79M | -120.72M | -75.98M | -12.83M |
Selling & General & Admin | 22.19M | 25.42M | 32.61M | 37.35M | 18.66M | 3.85M |
Research & Development | 73.7M | 58.75M | 49.59M | 86.13M | 51.05M | 8.6M |
Other Expenses | n/a | 20.96M | n/a | n/a | n/a | n/a |
Operating Expenses | 95.89M | 105.13M | 82.2M | 123.48M | 69.72M | 12.45M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 98.28M | 105.61M | 82.2M | 123.48M | 69.72M | 12.89M |
Income Tax Expense | 1.39M | -2.16M | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 62.14M | 58.45M | 39.9M | 33.03M | 32.22M | 34.31M |
Shares Outstanding (Diluted) | 62.14M | 58.45M | 39.9M | 33.03M | 32.22M | 34.31M |
EPS (Basic) | -1.28 | -1.32 | -1.85 | -3.57 | -2.53 | -0.37 |
EPS (Diluted) | -1.28 | -1.32 | -1.85 | -3.57 | -2.53 | -0.37 |
EBITDA | -73.72M | -65.51M | -71.86M | -120.01M | -75.33M | -12.38M |
EBIT | -78.24M | -68.5M | -73.79M | -120.72M | -75.98M | -12.83M |
Depreciation & Amortization | 4.51M | 2.98M | 1.93M | 709K | 647K | 444K |
Add to Watchlist
Select watchlists to add or remove PYXS